230 related articles for article (PubMed ID: 7949203)
21. 19-oxygenated derivatives of androst-4-ene-6,17-dione and androst-5-ene-4,17-dione as catalytic probes for the active site of aromatase.
Numazawa M; Yamada K; Kidokoro K
Biol Pharm Bull; 1999 Oct; 22(10):1134-6. PubMed ID: 10549872
[TBL] [Abstract][Full Text] [Related]
22. Structure-activity relationships of new A,D-ring modified steroids as aromatase inhibitors: design, synthesis, and biological activity evaluation.
Cepa MM; Tavares da Silva EJ; Correia-da-Silva G; Roleira FM; Teixeira NA
J Med Chem; 2005 Oct; 48(20):6379-85. PubMed ID: 16190763
[TBL] [Abstract][Full Text] [Related]
23. Aromatase inhibitors: past, present and future.
Séralini G; Moslemi S
Mol Cell Endocrinol; 2001 Jun; 178(1-2):117-31. PubMed ID: 11403901
[TBL] [Abstract][Full Text] [Related]
24. Substituted C19 steroid analogs as inhibitors of aromatase.
Brueggemeier RW; Snider CE; Counsell RE
Cancer Res; 1982 Aug; 42(8 Suppl):3334s-3337s. PubMed ID: 7083196
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and biological evaluation of 16E-arylidenosteroids as cytotoxic and anti-aromatase agents.
Bansal R; Guleria S; Thota S; Hartmann RW; Zimmer C
Chem Pharm Bull (Tokyo); 2011; 59(3):327-31. PubMed ID: 21372413
[TBL] [Abstract][Full Text] [Related]
26. Developing steroidal aromatase inhibitors-an effective armament to win the battle against breast cancer.
Yadav MR; Barmade MA; Tamboli RS; Murumkar PR
Eur J Med Chem; 2015 Nov; 105():1-38. PubMed ID: 26469743
[TBL] [Abstract][Full Text] [Related]
27. Studies directed toward a mechanistic evaluation of aromatase inhibition by androst-5-ene-7,17-dione. Time-dependent inactivation by the 19-nor and 5 beta, 6 beta-epoxy derivatives.
Numazawa M; Tachibana M
Steroids; 1997 Jul; 62(7):516-22. PubMed ID: 9253790
[TBL] [Abstract][Full Text] [Related]
28. Recent developments in steroidal and nonsteroidal aromatase inhibitors for the chemoprevention of estrogen-dependent breast cancer.
Ahmad I; Shagufta
Eur J Med Chem; 2015 Sep; 102():375-86. PubMed ID: 26301554
[TBL] [Abstract][Full Text] [Related]
29. 6beta,19-Bridged androstenedione analogs as aromatase inhibitors.
Komatsu S; Yaguchi A; Yamashita K; Nagaoka M; Numazawa M
Steroids; 2009 Nov; 74(12):884-9. PubMed ID: 19524602
[TBL] [Abstract][Full Text] [Related]
30. 6-Alkyl- and 6-arylandrost-4-ene-3,17-diones as aromatase inhibitors. Synthesis and structure-activity relationships.
Numazawa M; Oshibe M
J Med Chem; 1994 Apr; 37(9):1312-9. PubMed ID: 8176709
[TBL] [Abstract][Full Text] [Related]
31. Structure-activity relationships of 2alpha-substituted androstenedione analogs as aromatase inhibitors and their aromatization reactions.
Numazawa M; Handa W; Hasegawa C; Takahashi M
J Steroid Biochem Mol Biol; 2005 Dec; 97(4):353-9. PubMed ID: 16209922
[TBL] [Abstract][Full Text] [Related]
32. Biochemical and endocrine properties of a mechanism-based inhibitor of aromatase.
Johnston JO; Wright CL; Metcalf BW
Endocrinology; 1984 Aug; 115(2):776-85. PubMed ID: 6745181
[TBL] [Abstract][Full Text] [Related]
33. Biochemical and pharmacological development of steroidal inhibitors of aromatase.
Brueggemeier RW; Li PK; Chen HH; Moh PP; Katlic NE
J Steroid Biochem Mol Biol; 1990 Nov; 37(3):379-85. PubMed ID: 2257241
[TBL] [Abstract][Full Text] [Related]
34. New structure-activity relationships of A- and D-ring modified steroidal aromatase inhibitors: design, synthesis, and biochemical evaluation.
Varela C; Tavares da Silva EJ; Amaral C; Correia da Silva G; Baptista T; Alcaro S; Costa G; Carvalho RA; Teixeira NA; Roleira FM
J Med Chem; 2012 Apr; 55(8):3992-4002. PubMed ID: 22475216
[TBL] [Abstract][Full Text] [Related]
35. Stereochemistry of the functional group determines the mechanism of aromatase inhibition by 6-bromoandrostenedione.
Osawa Y; Osawa Y; Coon MJ
Endocrinology; 1987 Sep; 121(3):1010-6. PubMed ID: 3622372
[TBL] [Abstract][Full Text] [Related]
36. Growth suppression of MCF-7 human breast cancer cells by aromatase inhibitors: a new system for aromatase inhibitor screening.
Kitawaki J; Kim T; Kanno H; Noguchi T; Yamamoto T; Okada H
J Steroid Biochem Mol Biol; 1993 Mar; 44(4-6):667-70. PubMed ID: 8476780
[TBL] [Abstract][Full Text] [Related]
37. Structure-activity relationships for non-steroidal inhibitors of aromatase.
Banting L; Smith HJ; James M; Jones G; Nazareth W; Nicholls PJ; Hewlins MJ; Rowlands MG
J Enzyme Inhib; 1988; 2(3):215-29. PubMed ID: 3241182
[TBL] [Abstract][Full Text] [Related]
38. [Aromatase inhibitors: pharmacological aspects].
de Crémoux P
Bull Cancer; 2000 Dec; 87 Spec No():23-29. PubMed ID: 11250605
[TBL] [Abstract][Full Text] [Related]
39. Aromatase inhibition in JAr choriocarcinoma cells by 7alpha-arylaliphatic androgens.
Brueggemeier RW; Gilbert NE; Gu X; O'Reilly JM; Lovely CJ
J Steroid Biochem Mol Biol; 1997 Apr; 61(1-2):73-7. PubMed ID: 9328212
[TBL] [Abstract][Full Text] [Related]
40. Combating breast cancer with non-steroidal aromatase inhibitors (NSAIs): Understanding the chemico-biological interactions through comparative SAR/QSAR study.
Adhikari N; Amin SA; Saha A; Jha T
Eur J Med Chem; 2017 Sep; 137():365-438. PubMed ID: 28622580
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
